Imbruvica Europos Sąjunga - suomių - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

SIMDAX 2.5 mg/ml infuusiokonsentraatti, liuosta varten Suomija - suomių - Fimea (Suomen lääkevirasto)

simdax 2.5 mg/ml infuusiokonsentraatti, liuosta varten

orifarm oy - levosimendanum - infuusiokonsentraatti, liuosta varten - 2.5 mg/ml - levosimendaani

Thiotepa Riemser Europos Sąjunga - suomių - EMA (European Medicines Agency)

thiotepa riemser

esteve pharmaceuticals gmbh - tiotepa - hematopoietic stem cell transplantation; neoplasms - antineoplastiset aineet - thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients. thiotepa riemser is indicated, in combination with other chemotherapy medicinal products:with or without total body irradiation (tbi), as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (hpct) in haematological diseases in adult and paediatric patients;when high dose chemotherapy with hpct support is appropriate for the treatment of solid tumours in adult and paediatric patients.

Simdax 2.5 mg/ml infuusiokonsentraatti, liuosta varten Suomija - suomių - Fimea (Suomen lääkevirasto)

simdax 2.5 mg/ml infuusiokonsentraatti, liuosta varten

orion corporation - levosimendan - infuusiokonsentraatti, liuosta varten - 2.5 mg/ml - levosimendaani

Enerzair Breezhaler Europos Sąjunga - suomių - EMA (European Medicines Agency)

enerzair breezhaler

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Tezspire Europos Sąjunga - suomių - EMA (European Medicines Agency)

tezspire

astrazeneca ab - tezepelumab - astma - obstruktiivisten hengitystiesairauksien lääkkeet, - tezspire is indicated as an add-on maintenance treatment in adults and adolescents 12 years and older with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment.

DuoPlavin Europos Sąjunga - suomių - EMA (European Medicines Agency)

duoplavin

sanofi winthrop industrie - clopidogrel, acetylsalicylic acid - acute coronary syndrome; myocardial infarction - antitromboottiset aineet - duoplavin on tarkoitettu aterotromboottisten tapahtumien toissijaiseen ehkäisyyn aikuispotilailla, jotka jo käyttävät sekä klopidogreelia että asetyylisalisyylihappoa (asa). duoplavin is a fixed-dose combination medicinal product for continuation of therapy in:non st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction) including patients undergoing a stent placement following percutaneous coronary intervention (pci);st segment elevation acute myocardial infarction (stemi) in patients undergoing a stent placement) or medically treated patients eligible for thrombolytic/fibrinolytic therapy. lisätietoja, katso kohta 5.

Progressis injektioneste, emulsio Suomija - suomių - Fimea (Suomen lääkevirasto)

progressis injektioneste, emulsio

ceva santÉ animale - porcine reproductive and respiratory syndrome virus (prrsv), ina - injektioneste, emulsio

Srivasso 18 mikrog inhalaatiojauhe, kapseli, kova Suomija - suomių - Fimea (Suomen lääkevirasto)

srivasso 18 mikrog inhalaatiojauhe, kapseli, kova

boehringer ingelheim international gmbh - tiotropium bromide monohydrate - inhalaatiojauhe, kapseli, kova - 18 mikrog - tiotropiumbromidi

OXYNORM 50 mg/ml injektio-/infuusioneste, liuos Suomija - suomių - Fimea (Suomen lääkevirasto)

oxynorm 50 mg/ml injektio-/infuusioneste, liuos

mundipharma oy - oxycodoni hydrochloridum - injektio-/infuusioneste, liuos - 50 mg/ml - oksikodoni